Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.
Cediranib is a highly potent and selective inhibitor of the 3 vascular endothelial growth factor receptors and has a halflife suitable for once-daily oral dosing. It is currently in phase III development for the first-line treatment of metastatic colorectal cancer. This article summarizes the clinical development program, which includes 2 global phase III studies, HORIZON II and HORIZON III, in the first-line treatment setting and a phase II study in second-line treatment (HORIZON I).
Robertson
Jane D
JD
AstraZeneca, Alderley Park, Macclesfield, UK. jane.robertson@astrazeneca.com
Botwood
Nick A
NA
Rothenberg
Mace L
ML
Schmoll
Hans-Joachim
HJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use*; D016896:Treatment Outcome; D007211:Indoles
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005472:Fluorouracil; D002955:Leucovorin; D009944:Organoplatinum Compounds; D011799:Quinazolines; C500926:cediranib; D007211:Indoles